Streetbeat News

Regulatory

F

RIVN

TSLA

Automotive stocks, including TSLA, RIVN, and F, are experiencing a slight decline in premarket trading due to recession fears and tariff concerns in the US.

Portfolio Pulse from

March 04, 2025 | 2:00 pm

FBLG

FibroBiologics has filed a patent for a new method to modulate mitochondrial activity using fibroblast-based therapeutics. This approach could lead to new treatments for chronic conditions related to mitochondrial dysregulation.

Portfolio Pulse from

March 04, 2025 | 1:45 pm

IINN

Inspira Technologies announced positive results from a clinical study of its AI-powered HYLA blood sensor, achieving 96% accuracy. The company plans to continue clinical studies and aims for FDA submission in H2 2025.

Portfolio Pulse from

March 04, 2025 | 1:45 pm

BITW

BITW shares gained attention due to a NAV discount and Trump's pro-crypto stance. Trump's executive order on digital assets aims to create a Crypto Strategic Reserve, including major cryptocurrencies. The market reacted with a high-leverage trade on ETH and BTC, hinting at possible insider trading.

Portfolio Pulse from

March 04, 2025 | 1:45 pm

SOUN

SoundHound AI has postponed the release of its annual report, prompting Kehoe Law Firm to investigate potential securities fraud claims on behalf of investors. This development could impact investor confidence in the company.

Portfolio Pulse from

March 04, 2025 | 1:45 pm

CAT

President Trump's new trade tariffs have taken effect, causing a negative reaction in the stock market. Investors are advised to consider buying stocks that may benefit from these tariffs.

Portfolio Pulse from

March 04, 2025 | 1:30 pm

PRIV

The SPDR SSGA Apollo IG Public & Private Credit ETF (PRIV) faces potential liquidity issues due to its structure, which may not be suitable for illiquid assets. Historical examples like the Woodford fund scandal highlight the risks of liquidity mismatch in such funds.

Portfolio Pulse from

March 04, 2025 | 1:30 pm

ALZN

Alzamend Neuro, Inc. (Nasdaq: ALZN) announced the initiation of a Phase II clinical trial for AL001, targeting bipolar disorder, to begin in Q3 2025 at Massachusetts General Hospital.

Portfolio Pulse from

March 04, 2025 | 1:30 pm

MIRA

MIRA Pharmaceuticals has received approval to initiate a Phase 1 clinical trial for Ketamir-2, a novel oral ketamine analog for neuropathic pain. The trial will be conducted in Israel, with recruitment starting in Q1 2025.

Portfolio Pulse from

March 04, 2025 | 1:15 pm

BNRG

The European Commission has introduced the Clean Industrial Deal (CID), a comprehensive plan to address Europe's energy crisis and decarbonization needs. Brenmiller Energy is positioned to play a key role in realizing this vision.

Portfolio Pulse from

March 04, 2025 | 1:15 pm